Showing 1431-1440 of 10594 results for "".
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
https://reachmd.com/programs/cme/implementing-guideline-concordant-care-for-a-patient-with-newly-diagnosed-stage-iii-melanoma/36326/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
https://reachmd.com/programs/cme/data-driving-preferred-guideline-recommendations-in-first-line-therapy-for-metastatic-melanoma/36327/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.When GDMT Isn’t Enough: Understanding Residual Risk in Patients with HFrEF
https://reachmd.com/programs/cme/when-gdmt-isnt-enough-understanding-residual-risk-in-patients-with-hfref/51036/Drs. Bauersachs, Butler & Lam discuss persistent residual risk in HFrEF, the use of sGC stimulators to reduce risk, and supporting evidence for this approach.The Ambulatory HFrEF Blind Spot: Proactively Reducing CV Mortality Risk Despite Optimized GDMT
https://reachmd.com/programs/cme/the-ambulatory-hfref-blind-spot-proactively-reducing-cv-mortality-risk-despite-optimized-gdmt/48810/Drs. Bauersachs, Butler & Lam discuss persistent residual risk in HFrEF, the use of sGC stimulators to reduce risk, and supporting evidence for this approach.Do Not Delay: Timing, Triggers, and Identifying the Right Patient for Additional Therapies in HFrEF
https://reachmd.com/programs/cme/do-not-delay-timing-triggers-and-identifying-the-right-patient-for-additional-therapies-in-hfref/54633/Drs. Bauersachs, Butler & Lam discuss persistent residual risk in HFrEF, the use of sGC stimulators to reduce risk, and supporting evidence for this approach.Evidence at a Glance: The Totality of Evidence Impacting Clinical Decision-Making in Patients with HFrEF Without a Recent Worsening Event
https://reachmd.com/programs/cme/evidence-at-a-glance-the-totality-of-evidence-impacting-clinical-decision-making-in-patients-with-hfref-without-a-recent-worsening-event/54634/Drs. Bauersachs, Butler & Lam discuss persistent residual risk in HFrEF, the use of sGC stimulators to reduce risk, and supporting evidence for this approach.GDMT Is Working Fine, Why Add More Therapies? The Clinical Rationale for Layering Therapies in Patients with HFrEF
https://reachmd.com/programs/cme/gdmt-is-working-fine-why-add-more-therapies-the-clinical-rationale-for-layering-therapies-in-patients-with-hfref/54632/Drs. Bauersachs, Butler & Lam discuss persistent residual risk in HFrEF, the use of sGC stimulators to reduce risk, and supporting evidence for this approach.GDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?
https://reachmd.com/programs/cme/gdmt-is-working-fine-so-why-add-more-therapies-for-patients-with-hfref/48811/Which patients with HFrEF may benefit from additional evidence-based therapies beyond GDMT? Join Drs. Lam and Bauersachs in this case-based discussion.Safety, Clinical Integration, and the Emerging Fifth Pillar in HF Practice
https://reachmd.com/programs/cme/safety-clinical-integration-and-the-emerging-fifth-pillar-in-hf-practice/54635/Drs. Bauersachs, Butler & Lam discuss persistent residual risk in HFrEF, the use of sGC stimulators to reduce risk, and supporting evidence for this approach.Living With Systemic Mastocytosis: Bridging Clinical Decisions and Patient Realities
https://reachmd.com/programs/cme/living-with-systemic-mastocytosis-bridging-clinical-decisions-and-patient-realities/54389/Join us to explore the disease burden of systemic mastocytosis, evidence-based personalized care, and using multidisciplinary strategies to improve outcomes.